In order to clinically develop the BCR-ABL degraders, it is important to examine the protein knockdown and anti-proliferation activities in primary CML cells and CD34+ stem cells, which allows us to estimate the on- and off-target effects. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.